


Aplaviroc hydrochloride

Chemical Properties

CAS No. :	461023-63-2
Formula:	C ₃₃ H ₄₄ ClN ₃ O ₆
Molecular Weight:	614.17
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Aplaviroc is a human cellular CC chemokine receptor 5 (CCR5) entry inhibitor. Aplaviroc binds specifically to CCR5 and demonstrates potent anti-human immunodeficiency virus activity in vitro in the subnanomolar range. In vitro studies show that aplaviroc selectively inhibits the binding of a particular monoclonal antibody, 45531, to CCR5.
Targets(IC50)	Others,HIV Protease,CCR

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6282 mL	8.1411 mL	16.2821 mL
5 mM	0.3256 mL	1.6282 mL	3.2564 mL
10 mM	0.1628 mL	0.8141 mL	1.6282 mL
50 mM	0.0326 mL	0.1628 mL	0.3256 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. *Antiviral Res.* 2009 Jul;83(1):86-9. doi: 10.1016/j.antiviral.2009.02.199. Epub 2009 Mar 9. PubMed PMID: 19501260.

Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). *HIV Med.* 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x. PubMed PMID: 19200175.

Nolan KM, Del Prete GQ, Jordan AP, Haggarty B, Romano J, Leslie GJ, Hoxie JA. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. *J Virol.* 2009 Apr;83(8):3798-809. doi: 10.1128/JVI.01751-08. Epub 2009 Feb 4. PubMed PMID: 19193800; PubMed Central PMCID: PMC2663279.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team. Virologic failure in therapy-naïve subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. *Antimicrob Agents Chemother.* 2009 Mar;53(3):1124-31. doi: 10.1128/AAC.01057-08. Epub 2008 Dec 15. PubMed PMID: 19075068; PubMed Central PMCID: PMC2650553.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481